Brenno Pastò
A5026509556- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Lung Cancer Research Studies
- Reproductive Biology and Fertility
- Cancer Risks and Factors
- Nutrition and Health in Aging
- Oral health in cancer treatment
- Gastric Cancer Management and Outcomes
- BRCA gene mutations in cancer
- HER2/EGFR in Cancer Research
- Esophageal Cancer Research and Treatment
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Treatments and Mutations
- Estrogen and related hormone effects
- Gene expression and cancer classification
Istituti di Ricovero e Cura a Carattere Scientifico
2023-2024
University of Udine
2023-2024
Centro di Riferimento Oncologico
2023-2024
Importance Young women with breast cancer who have germline pathogenic variants in BRCA1 or BRCA2 face unique challenges regarding fertility. Previous studies demonstrating the feasibility and safety of pregnancy survivors included limited data BRCA carriers. Objective To investigate cumulative incidence disease-free survival young are Design, Setting, Participants International, multicenter, hospital-based, retrospective cohort study conducted at 78 participating centers worldwide. The...
The emerging era of precision medicine is characterized by an increasing availability targeted anticancer therapies and the parallel development techniques to obtain more refined molecular data, whose interpretation may not always be straightforward. Molecular tumor boards gather various professional figures, in order leverage analysis data provide prognostic predictive insights for clinicians. In addition healthcare development, they could also become a tool promote knowledge research...
Abstract Background: In patients (pts) with estrogen receptor (ER) positive (pos), HER2 negative (neg) MBC, the absence of progesterone (PR) expression is generally associated a poorer endocrine therapy (ET) response and an unfavorable prognosis. However, real-time molecular changes during ET according to PR status are still not fully understood. The aim this study was examine prognostic impact its association methylation levels ESR1 promoters A (promA) B (promB) at different timepoints in...
Abstract Background: Cyclin-dependent kinase inhibitors (CDK4/6i) in combination with endocrine therapy (ET) represent the cornerstone for management of HR positive, HER2 negative MBC. However, lack prospective cohorts comparing distinctions among palbociclib (PAL), ribociclib (RIB) and abemaciclib (ABE) poses a significant clinical knowledge gap. The aim this ancillary analysis was to explore differential impact CDK4/6i by leveraging new ctDNA biomarkers study. Methods: A total 114 patients...
e16110 Background: The optimal management of locally advanced gastroesophageal junction adenocarcinoma (LAGEJad) is not fully established yet. Both neoadjuvant chemoradiotherapy (CRT) and perioperative taxane-based triplet chemotherapy (CT) are acknowledged treatment options for Siewert I II cancers. In this retrospective study, we aimed to assess the safety outcomes an intensified preoperative regimen combining CT CRT. Methods: We conducted a analysis cohort comprising 16 consecutive HER2...
Abstract Background: Over the last years, management of patients with node positive early breast cancer has gone through important innovations. On medical side, new targeted therapies such as olaparib and abemaciclib have been introduced, promising results on invasive disease-free survival. Moreover, sparing axillary lymph dissection proven to be noninferior in terms overall However, no tools are currently available predict involvement before definitive surgical evaluation. The aim study was...